openPR Logo
Press release

Ensuring Analytical Precision: Lenacapavir Impurity Standards & Sodium Reference from Aquigen Bio

06-30-2025 11:01 AM CET | Chemicals & Materials

Press release from: Aquigen Bio Sciences

Ensuring Analytical Precision: Lenacapavir Impurity

Ensuring Analytical Precision: Lenacapavir Impurity Standards & Sodium Reference from Aquigen Bio

As lenacapavir (GS‐6207/Sunlenca) gains momentum in HIV prevention and treatment, providing accurate reference standards becomes critical. Aquigen Bio offers high-purity impurity standards-Lenacapavir Impurity‐7, Impurity‐9-plus Lenacapavir Sodium, all designed to support method development, quality control, and regulatory compliance in pharmaceutical workflows.

What is Lenacapavir?
Lenacapavir is a first-in-class HIV‐1 capsid inhibitor, approved by the FDA in December 2022, and marketed under names like Sunlenca and Yeztugo. Its mechanism targets multiple stages of viral replication, and it's administered in long-acting injectable or oral forms-providing biannual protection as a pre‐exposure prophylaxis (PrEP) option

Lenacapavir Impurity Standards: Impurity‐7 & Impurity‐9
Aquigen Bio provides well-characterized impurity standards from the lenacapavir synthesis pathway:

• Lenacapavir Impurity‐7
https://aquigenbio.com/product/lenacapavir-impurity-7/
A key process-related impurity. Essential for:
Method validation via HPLC, LC‐MS

Monitoring trace impurities in batches

Ensuring compliance with pharmacopeial and regulatory thresholds (e.g. ICH Q3A)

• Lenacapavir Impurity‐9
https://aquigenbio.com/product/lenacapavir-impurity-9/
A critical degradation impurity that forms during stability studies. Used for:
Accelerated and long-term stability analysis

Forced-degradation studies

Quantitative reporting during regulatory submissions

These impurity standards enable accurate detection and quantification-ensuring analysts meet ICH Q3A/B and US FDA regulatory criteria

Lenacapavir Sodium: High-Purity API Reference
https://aquigenbio.com/product/lenacapavir-sodium/
Lenacapavir Sodium (CAS 2283356‐12‐5), the sodium salt form, is available from Aquigen Bio with >98% purity and comprehensive documentation. Applications include:
Reference standard in QC laboratories

Calibration standard for method validation (AMV)

ANDA filing material and pharmacopeial traceable reference

Supplied with full coA, MS/NMR data, and stability profiles, this standard supports both routine QC checks and high-level regulatory procedures

Why High-Quality Lenacapavir Standards Are Essential
Analytical Integrity: Minimize false positives and misidentification

Regulatory Security: Ready for support in DMF/ANDA/NDA dossiers

Risk Reduction: Track degradation and synthesis impurities during shelf life

Workflow Efficiency: Pre-characterized standards save lab time and promote compliance

High-quality CRM standards reduce development delays and strengthen lab credentials in the eyes of reviewers.

Conclusion
With lenacapavir gaining prominence as a breakthrough HIV therapeutic, having reliable impurity and API standards is no longer optional-it's essential. Aquigen Bio delivers robust, validated materials that help pharmaceutical labs uphold regulatory standards, reduce risk, and accelerate development. Explore their catalog to secure your analytical advantage.

Aquigen Bio Sciences
281/1, Plot No 41,
Hinjawadi - Pirangut Rd,
Kasar Amboli, Pirangut,
Pune, Maharashtra 412108
Visit: www.aquigenbio.com

Aquigen Bio Sciences stands as India's premier resource for high-quality N-Nitroso impurity standards, impelling advancements in pharmaceutical research and manufacturing. Specializing in providing precise impurity standards - including degradation impurities, process impurities, and deuterated isotopes - Aquigen Bio Sciences empowers the industry to comply with the most rigorous global regulations. The contract research organization's commitment to precision and reliability makes it the trusted partner for addressing complex issues like N-Nitroso impurities in pharmaceuticals.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ensuring Analytical Precision: Lenacapavir Impurity Standards & Sodium Reference from Aquigen Bio here

News-ID: 4085002 • Views:

More Releases from Aquigen Bio Sciences

Aquigen Bio Launches High-Purity Impurity Standards for Pizotifen, Padimate-O & Pacritinib
Aquigen Bio Launches High-Purity Impurity Standards for Pizotifen, Padimate-O & …
Aquigen Bio, a trusted provider of pharmaceutical reference standards and research tools, is pleased to announce the launch of new impurity standards for three critical pharmaceutical and cosmeceutical compounds: Pizotifen, Padimate-O, and Pacritinib. As the pharmaceutical and personal care industries face growing regulatory scrutiny and an increasing demand for analytical precision, Aquigen Bio continues to deliver certified reference materials (CRMs) that empower laboratories to meet quality benchmarks and support safe, compliant
Advancing Pharmaceutical Precision with Remifentanil EP Impurity L from Aquigen Bio
Advancing Pharmaceutical Precision with Remifentanil EP Impurity L from Aquigen …
In the high-stakes world of pharmaceutical manufacturing, precision, purity, and compliance are non-negotiable. Regulatory frameworks like the European Pharmacopoeia (EP) set clear expectations for drug safety and efficacy, with stringent requirements for impurity profiling. Remifentanil EP Impurity L-now available from Aquigen Bio-is a key standard developed to help drug developers and quality control teams meet these critical demands. Click link to know more about Remifentanil EP Impurity L https://aquigenbio.com/product/remifentanil-ep-impurity-l/ This impurity, specified in
Advancing Pharmaceutical Analysis with Bedaquiline Impurity Standards: Aquigen Bio's Comprehensive Portfolio
Advancing Pharmaceutical Analysis with Bedaquiline Impurity Standards: Aquigen B …
In the dynamic landscape of pharmaceutical development, impurity profiling plays a pivotal role in ensuring drug safety, efficacy, and regulatory compliance. With rising regulatory scrutiny and evolving analytical methodologies, the need for high-purity impurity standards has never been greater-especially for critical anti-tuberculosis drugs like Bedaquiline. At Aquigen Bio, our dedication to analytical integrity and pharmaceutical innovation has led to the development of a comprehensive suite of Bedaquiline impurity standards. These compounds

All 4 Releases


More Releases for Lenacapavir

HIV Antivirals Market Future Demands, Regional Developments and Industry Competi …
According to Future Market Insights, the global HIV antiviral market was around US$ 29.4 Bn in 2021 and is expected to exhibit a CAGR of close to 4.4% over the forecast period (2022-2032). The demand for HIV antivirals is increasing due to growing prevalence of HIV across the globe. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS), approximately 37.7 million people were infected with HIV in the
Injectable Drugs Market is projected to be valued at US$ 937.0 Billion by the en …
[341 Pages Report] Cancer, cardiovascular diseases, and metabolic diseases like diabetes, are the main cause of mortality and disability in present times. Even with the understanding of scientific disease indications, it is crucial to elevate diagnosis and control the symptoms and signs of illness. According to the Future Market Insights' analysis, the injectable drugs market is set to grow at a 5.8% CAGR over the assessment period. As per the report,
Injectable Drugs Market Share 2022, Global Trends, Demand Factors And Outlook
According to the Future Market Insights' analysis, the injectable drugs market is set to grow at a 5.8% CAGR over the assessment period. As per the report, the market is projected to be valued at US$ 937.0 Bn by the end of 2032. Injectable Drugs Market to Grow at 5.85 through 2032 Amid Increasing Utilization of Intravenous Drug Delivery Cancer, cardiovascular diseases, and metabolic diseases like diabetes, are the main cause of